our pipeline
Development Pipeline
Two Phase 3 programs evaluating ersodetug for the treatment of congenital and tumor hyperinsulinism.
At Rezolute, we are committed to delivering novel therapies for rare diseases to significantly improve the quality of life for patients and their families.
Our development pipeline includes ersodetug, a fully human monoclonal antibody that has the potential to be universally effective at treating the devastating effects of hypoglycemia due to all forms of hyperinsulinism.
Program
Indication
- Phase 1 Ph 1
- Phase 2 Ph 2
- Phase 3 Ph 3
Next Milestone
Congenital Hyperinsulinism
Tumor Hyperinsulinism
Topline data
2H 2025
Topline data
2H 2026
Program
Indication
Congenital Hyperinsulinism
- Phase 1 Ph 1
- Phase 2 Ph 2
- Phase 3 Ph 3
Next Milestones
Topline data
2H 2025
Indication
Tumor Hyperinsulinism
- Phase 1 Ph 1
- Phase 2 Ph 2
- Phase 3 Ph 3
Next Milestones
Topline data
2H 2026